| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:38 UTC |
|---|
| HMDB ID | HMDB0014490 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Alfuzosin |
|---|
| Description | Alfuzosin is only found in individuals that have used or taken this drug. It is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia ]Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. |
|---|
| Structure | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1 InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) |
|---|
| Synonyms | | Value | Source |
|---|
| Alfuzosina | ChEBI | | Alfuzosine | ChEBI | | Alfuzosinum | ChEBI | | Xatral | Kegg | | Alfusosine | HMDB | | N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide | HMDB | | UroXatral | HMDB | | Alfusozine | HMDB | | Urion | HMDB | | Alfuzosin hydrochloride | HMDB | | Alphuzosine | HMDB | | Alfetim | HMDB | | Benestan | HMDB |
|
|---|
| Chemical Formula | C19H27N5O4 |
|---|
| Average Molecular Weight | 389.4488 |
|---|
| Monoisotopic Molecular Weight | 389.206304377 |
|---|
| IUPAC Name | N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide |
|---|
| Traditional Name | alfuzosin |
|---|
| CAS Registry Number | 81403-80-7 |
|---|
| SMILES | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1 |
|---|
| InChI Identifier | InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) |
|---|
| InChI Key | WNMJYKCGWZFFKR-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazanaphthalenes |
|---|
| Sub Class | Benzodiazines |
|---|
| Direct Parent | Quinazolinamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Quinazolinamine
- Anisole
- Dialkylarylamine
- Alkyl aryl ether
- Aminopyrimidine
- Pyrimidine
- Imidolactam
- Benzenoid
- Heteroaromatic compound
- Tetrahydrofuran
- Carboximidic acid
- Carboximidic acid derivative
- Dialkyl ether
- Ether
- Oxacycle
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.28 g/L | Not Available | | LogP | 1.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.23 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.167 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.21 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 74.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1596.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 193.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 140.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 167.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 78.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 293.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 394.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 536.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 770.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 282.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1152.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 256.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 266.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 452.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 294.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 35.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Alfuzosin,1TMS,isomer #1 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C)=C2C=C1OC | 3668.6 | Semi standard non polar | 33892256 | | Alfuzosin,1TMS,isomer #1 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C)=C2C=C1OC | 3270.9 | Standard non polar | 33892256 | | Alfuzosin,1TMS,isomer #1 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C)=C2C=C1OC | 5231.1 | Standard polar | 33892256 | | Alfuzosin,1TMS,isomer #2 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N)=C2C=C1OC | 3539.2 | Semi standard non polar | 33892256 | | Alfuzosin,1TMS,isomer #2 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N)=C2C=C1OC | 3303.0 | Standard non polar | 33892256 | | Alfuzosin,1TMS,isomer #2 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N)=C2C=C1OC | 5275.9 | Standard polar | 33892256 | | Alfuzosin,2TMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C2C=C1OC | 3595.1 | Semi standard non polar | 33892256 | | Alfuzosin,2TMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C2C=C1OC | 3322.6 | Standard non polar | 33892256 | | Alfuzosin,2TMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C2C=C1OC | 4837.1 | Standard polar | 33892256 | | Alfuzosin,2TMS,isomer #2 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3563.9 | Semi standard non polar | 33892256 | | Alfuzosin,2TMS,isomer #2 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3281.4 | Standard non polar | 33892256 | | Alfuzosin,2TMS,isomer #2 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 4790.3 | Standard polar | 33892256 | | Alfuzosin,3TMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3527.8 | Semi standard non polar | 33892256 | | Alfuzosin,3TMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3341.6 | Standard non polar | 33892256 | | Alfuzosin,3TMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 4427.3 | Standard polar | 33892256 | | Alfuzosin,1TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3841.9 | Semi standard non polar | 33892256 | | Alfuzosin,1TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3457.9 | Standard non polar | 33892256 | | Alfuzosin,1TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 5122.6 | Standard polar | 33892256 | | Alfuzosin,1TBDMS,isomer #2 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N)=C2C=C1OC | 3727.1 | Semi standard non polar | 33892256 | | Alfuzosin,1TBDMS,isomer #2 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N)=C2C=C1OC | 3487.0 | Standard non polar | 33892256 | | Alfuzosin,1TBDMS,isomer #2 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N)=C2C=C1OC | 5212.1 | Standard polar | 33892256 | | Alfuzosin,2TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3923.0 | Semi standard non polar | 33892256 | | Alfuzosin,2TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3681.8 | Standard non polar | 33892256 | | Alfuzosin,2TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4771.3 | Standard polar | 33892256 | | Alfuzosin,2TBDMS,isomer #2 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3954.5 | Semi standard non polar | 33892256 | | Alfuzosin,2TBDMS,isomer #2 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3712.7 | Standard non polar | 33892256 | | Alfuzosin,2TBDMS,isomer #2 | COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4731.1 | Standard polar | 33892256 | | Alfuzosin,3TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4065.5 | Semi standard non polar | 33892256 | | Alfuzosin,3TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3907.3 | Standard non polar | 33892256 | | Alfuzosin,3TBDMS,isomer #1 | COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4486.3 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Alfuzosin GC-MS (Non-derivatized) - 70eV, Positive | splash10-00fr-9244000000-7f0f72006d4f335adfd0 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Alfuzosin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-000i-0009000000-b390e2d32ee38fb79cf9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-00dr-0039000000-1058f618ea52b7aa95e6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-0aos-0195000000-97624e7dcce906c3a1ee | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-0udi-0391000000-6d58b29a79c5af262723 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-0udi-1970000000-b3cb9821b3584d86539f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-0i6s-1920000000-50ca3c071a5548796b3a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-014i-5900000000-b3a86e227650a23790ec | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-014i-9400000000-9929aaf0359abea0c166 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOF | splash10-014i-9100000000-b3dba930d4cfe0d28a8e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-0006-0009000000-58fd75abdf178ea1b331 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-0006-0119000000-90a7799e494035d224e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-0abi-5791000000-648d5529faeac9e35dc0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-00di-9260000000-591f2bacf7d82aeba7e3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-00di-9250000000-d107a0e9675604325bb1 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-00di-9340000000-f708562f3998488d7fce | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-00di-7910000000-3fe44ce2a42f727569e2 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-05fr-8900000000-dca38c682ad0b6c90b46 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOF | splash10-0bvl-9300000000-bad5c36d48e0e93a82aa | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alfuzosin , positive-QTOF | splash10-0006-0249000000-93552ff8c72ff220f172 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alfuzosin 10V, Positive-QTOF | splash10-0006-0092000000-4b7c2dae5894c14b8575 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alfuzosin 20V, Positive-QTOF | splash10-006x-1090000000-a62c896d99f7b9d73c0a | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alfuzosin 40V, Positive-QTOF | splash10-000i-3090000000-381d1c6c96f3e65c44e0 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alfuzosin 10V, Negative-QTOF | splash10-000i-1139000000-3af55917407f4facdb0b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alfuzosin 20V, Negative-QTOF | splash10-00yi-4193000000-b8b9ec6006943f78ab01 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alfuzosin 40V, Negative-QTOF | splash10-017i-6390000000-a64c36b6d4e976a6272f | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|